HDAC Inhibitors

 |  Home  |  Vorinostat  |  CI-994  |  MS-275  |  BML-210  |  M344  |  NVP-LAQ824  |  Panobinostat  |  Mocetinostat  |  PXD101  | 


BML-210 is a novel histone deacetylase inhibitor with putative effects on leukemia cell growth, differentiation and apoptosis. BML-210 is comparable with a well known HDAC inhibitor, phenyl butyrate, in its ability to cause cytotoxic effects dependent on exposure time and dose.


IUPAC Name: N-(2-aminophenyl)-N'-phenyloctanediamide
Molecular Weight: 339.44 g/mol
Molecular Formula: C20H25N3O2
SMILES: Nc1ccccc1NC(=O)CCCCCCC(=O)Nc2ccccc2
CAS Number: 537034-17-6
Melting point: 168-170 °C
Solubility: 10 mg/mL in ethanol; 25 mg/mL in DMSO
2D Molfile: Get the molfile
Synonyms: BML210; N-(2-aminophenyl)-N'-phenyl-octanediamide

BML-210 could be a promising antileukemic agent to induce apoptosis and to modulate differentiation through the modulation of histone acetylation and gene expression.

1) Borutinskaite VV, Navakauskiene R, Magnusson KE. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Ann N Y Acad Sci. 2006 Dec;1091:346-55.
2) Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol. 2006 Nov 7;549(1-3):9-18.
3) Herman D, Jenssen K et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006 Oct;2(10):551-8.


 |  CBHA  |  PCI-24781  |  ITF2357  |  Valproic Acid  |  Trichostatin A  |  Sodium Butyrate  |